Company Overview
Snapshot
Founded in December 2015, Sade Group operates with 1–10 employees. The company gained significant attention in May 2019 when Ori Yehudai, following the $7.1 billion sale of Frutarom, joined as active chairman and investor.
Business overview
Sade Group is a Health Tech & Life Sciences company focused on pharmaceutical products derived from cannabis. The company developed ASAYA, a platform that optimizes clinical outcomes for medical cannabis treatments through big data analysis and algorithms based on expert best practices. ASAYA integrates real-world patient outcomes with human and machine intelligence, utilizing machine learning, IoT, mobile applications, and predictive analytics to provide guidance for medical cannabis use. Sade Group serves the medical cannabis ecosystem, including healthcare professionals, patients, growers, and researchers.
Strategic signal
In May 2019, Ori Yehudai, a prominent figure in the industry after the $7.1 billion sale of Frutarom, joined. This move signaled strong validation for Sade Group's strategic direction and potential within the medical cannabis sector, attracting investor interest and providing significant leadership experience.
Log in to access full profile ›Company Intelligence Q&A
- What is Sade Group's primary focus?
- Sade Group focuses on developing cannabis-based pharmaceutical products and optimizing medical cannabis treatment outcomes through its ASAYA platform.
- What technology does the ASAYA platform utilize?
- The ASAYA platform integrates machine learning, IoT, mobile applications, and predictive analytics to provide practical guidance for medical cannabis care.
- When was Sade Group founded?
- Sade Group was founded in December 2015.
- Who joined Sade Group as active chairman and investor in May 2019?
- In May 2019, Ori Yehudai joined.
- What was the outcome of Ori Yehudai's involvement with Sade Group?
- In July 2019, Ori Yehudai departed from Sade Group after approximately two months in his role.